DUBLIN, March 4, 2016 /PRNewswire/ --
Research and Markets (http://www.researchandmarkets.com/research/t5czwt/solid_tumor) has announced the addition of the "Solid Tumor Testing Market in the US 2016-2020" report to their offering.
This comprehensive report predicts that the solid tumor testing market in the US will grow with a CAGR of 11.1% during the 2016-2020 period.
Commenting on the report, an analyst from the research team said: Ready-to-use reagents offer many advantages such as avoiding calculation, dilution, infection, and pipetting errors; and also save time. The focus on disease treatment and gaining accurate results through sample analysis will boost the consumption of ready-to-use reagents during the forecast period.
According to the report, Proteins and genes control various functions of the body. Any defect in a particular protein or gene structure will result in the occurrence of specific disorders. The development of personalized drugs depends on the identification and study of protein and gene expressions. These personalized medicines are regulated and labeled along with a specific diagnostic test, referred to as companion diagnostic.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the strengths and weaknesses of the key vendors?
- Abbott Molecular
- Agilent Technologies (Dako)
- Beckman Coulter
- Roche Diagnostics
- 20/20 GeneSystems
- Adaptive Biotechnologies
- Advanced Cell Diagnostics
- Agena Bioscience
- Ambry Genetics
- Avant Diagnostics
- Biological Dynamics
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Healthcare reform in US
PART 06: Reimbursement and coverage: An overview
PART 07: Market landscape
PART 08: Market segmentation by technology
PART 09: Market segmentation by cancer type
PART 10: Market drivers
PART 11: Impact of drivers
PART 12: Market challenges
PART 13: Impact of drivers and challenges
PART 14: Market trends
PART 15: Vendor landscape
PART 16: Appendix
PART 17: About Author
For more information visit http://www.researchandmarkets.com/research/t5czwt/solid_tumor
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets